A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system

• मुख्य लेखकों: Lisha Wu (लेखक), Maosheng Xu (लेखक), Xueqin Li (लेखक), Dilinuer Aierken (लेखक), Jinxiu Yu (लेखक), Tao Qin (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

IntroductionSotorasib and adagrasib have been widely used for the non-small cell lung cancer (NSCLC) patients harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. It's necessary to assess their safety profiles in the real-world population.MethodsA retrospective pharmacovig...